title: Optimal cytokine stimulation for the enhanced generation of leukemic dendritic cells in short-term culture.
abstract: Dendritic cells (DCs) are professional antigen presenting cells derived from myeloid or lymphoid precursors. Functional DCs have been generated from the malignant counterpart of these precursor cells. Herein, we describe the generation of DCs from different leukemias and determine the optimal culture conditions with minimal manipulation. Primary leukemic cells were cultured for 1, 3, and 5 days in 11 different cytokine combinations and analyzed for the expression of a mature DC phenotype. Optimal growth and DC characteristics were obtained with GM-CSF, FL, and SCF in 3-5 day cultures, suggesting a practical strategy for the immunotherapy of leukemia.
authors.affiliation: The University of Rochester Medical Center, Department of Internal Medicine, Hematology/Oncology Unit, Box 610, Rochester, NY 14642, USA. n.panoskaltsis@ic.ac.uk
authors.forename: Nicki
authors.initials: N
authors.lastname: Panoskaltsis
authors.forename: Todd J
authors.initials: TJ
authors.lastname: Belanger
authors.forename: Jane L
authors.initials: JL
authors.lastname: Liesveld
authors.forename: Camille N
authors.initials: CN
authors.lastname: Abboud
mesh_terms: D000208:Acute Disease; D000368:Aged; D002452:Cell Count; D002454:Cell Differentiation / Q000187:drug effects; D002675:Child, Preschool; D016207:Cytokines / Q000494:pharmacology*; D003713:Dendritic Cells / Q000166:cytology*; D005260:Female; D005434:Flow Cytometry; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D007938:Leukemia / Q000473:pathology*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000473:pathology; D007951:Leukemia, Myeloid / Q000473:pathology; D015477:Leukemia, Myelomonocytic, Chronic / Q000473:pathology; D008297:Male; D008858:Microscopy, Phase-Contrast; D008875:Middle Aged; D014411:Neoplastic Stem Cells / Q000166:cytology / Q000187:drug effects*; D010641:Phenotype; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000473:pathology; D011518:Proto-Oncogene Proteins / Q000494:pharmacology; D020794:Receptor Protein-Tyrosine Kinases / Q000494:pharmacology; D011993:Recombinant Fusion Proteins / Q000494:pharmacology; D019089:Stem Cell Factor / Q000494:pharmacology; D013601:T-Lymphocytes / Q000276:immunology; D014407:Tumor Cells, Cultured / Q000187:drug effects; D040281:Vascular Endothelial Growth Factor Receptor-1
chemical_list: D016207:Cytokines; D011518:Proto-Oncogene Proteins; D011993:Recombinant Fusion Proteins; D019089:Stem Cell Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D020794:Receptor Protein-Tyrosine Kinases; D040281:Vascular Endothelial Growth Factor Receptor-1